Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 4,152 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares of the company’s stock, valued at $9,549,268.05. The trade was a 2.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $70,055.70.

Hims & Hers Health Stock Down 26.1 %

NYSE HIMS opened at $49.10 on Friday. The company has a 50-day simple moving average of $35.05 and a two-hundred day simple moving average of $25.76. Hims & Hers Health, Inc. has a 12-month low of $9.25 and a 12-month high of $72.98. The firm has a market cap of $10.73 billion, a price-to-earnings ratio of 111.58 and a beta of 1.35.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock worth $202,556,000 after buying an additional 8,364,000 shares during the period. Renaissance Technologies LLC raised its holdings in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after buying an additional 4,145,305 shares during the period. Finally, State Street Corp grew its holdings in Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after acquiring an additional 206,078 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on HIMS. TD Cowen restated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday. Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and upped their price objective for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $28.53.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.